The Advances in Genome Biology and Expertise (AGBT) assembly celebrated its 25th anniversary in sunny Marco Island, Florida, with the customary combine of massive title audio system addressing researchers and executives within the next-generation sequencing (NGS), single cell, and spatial fields (together with Ewan Birney, PhD, deputy director of EMBL) and past (former U.S. President Invoice Clinton). Many of the consideration centered on product bulletins by key firms within the subject and those who want to be, a lot of them are summarized beneath.
This A-Record presents two lists of sequencing instrument suppliers. One record contains eight firms that present NGS devices. The opposite contains three firms that present Sanger sequencing-based devices. (One firm, Thermo Fisher Scientific, seems in each lists). Additionally listed individually are three firms whose sequencing choices consist primarily of workflow options—Agilent Applied sciences, QIAGEN, and Revvity. As with final yr’s A-Record, every firm is listed by title adopted by a brief description of their current exercise.
Not included this yr is Singular Genomics. Over the previous yr, Singular has pivoted to spatial sequencing by its G4X® Spatial Sequencer, asserting an early entry program in February with preliminary shipments deliberate for June. On February 21, a Deerfield Administration affiliate closed on its acquisition of Singular for $20 a share—a $50.2 million deal based mostly on Singular’s 2.51 million excellent shares, based on FactSet information. The deal took Singular non-public and altered its management, with a reconstituted board and a change of CEOs.
Suppliers of NGS Instrumentation |
Factor BiosciencesAll through 2025, Factor Biosciences plans to roll out a sequence of upgrades or “Innovation Roadmap” for the top-tier AVITI24™ sequencing system it launched final yr. Amongst enhancements set for the second half of this yr are direct in-sample sequencing for a variety of latest use circumstances, together with fully library-prep free, unbiased complete transcriptome, and focused RNA sequencing. Privately-held Factor disclosed an estimated 2024 income of roughly $60 million in January on the 43rd Annual J.P. Morgan Healthcare Convention. |
IlluminaIllumina has introduced a spatial know-how program designed to assist researchers study the spatial proximity of hundreds of thousands of cells per experiment, set for industrial launch in 2026. The longtime NGS chief additionally introduced a single cell collaboration with Broad Medical Labs, and a collaboration with Nvidia to use genomics and AI to research and interpret multiomic information in drug discovery, medical analysis, and human well being. In March, China banned the import of Illumina sequencers, in obvious retaliation for President Donald Trump levying tariffs on the nation. Illumina completed 2024 with a $1.223 billion internet loss on income of $4.372 billion. |
MGI TechMGI Tech has unveiled by U.S. subsidiary Full Genomics two new upgraded variations of its DNBSEQ next-gen sequencing system. One is DNBSEQ-T1+, a mid-throughput instrument designed to finish a paired finish 150 sequencing workflow in 24 hours with Q40 accuracy, a throughput vary of 25–1,200 Gb, and a most capability exceeding 1 Tb day by day. The opposite new sequencer, DNBSEQ-E25 Flash, is an upgraded model of the present transportable DNBSEQ-E25 sequencer that leverages AI-optimized protein engineering for enhanced sign depth and precision, constructing on self-luminescence know-how and a CMOS-based stream cell. |
Oxford Nanopore Applied sciencesDeclaring 2025 “the yr of the proteome,” Oxford Nanopore Applied sciences co-founder and CEO Gordon Sanghera has highlighted his firm’s dedication over the following 5 years to mix proteomics with multiomics in its menu of sequencing choices. In February, Oxford Nanopore introduced a veterinary diagnostics collaboration with PathoSense designed to consolidate a number of conventional infectious illness exams into one inexpensive and accessible resolution powered by Oxford Nanopore’s sequencing know-how, together with the MinION system’s scalable capabilities. ONT completed final yr with a lack of £146.2 million ($189.7 million) on income of £183.1 million ($237.6 million). |
RocheRoche generated buzz at AGBT after introducing its SBX (Sequencing by Growth) know-how. SBX makes use of biochemical conversion to encode DNA right into a surrogate molecule referred to as an Xpandomer (50x longer than goal DNA) and encodes the DNA sequence data in giant, excessive signal-to-noise reporters. In keeping with Roche, that permits extremely correct single-molecule nanopore sequencing utilizing a Complementary Steel Oxide Semiconductor (CMOS)-based sensor module. Roche Sequencing Options is inside Roche’s Diagnostics Division, which final yr generated CHF 14.324 billion ($15.954 billion) in income. |
Thermo Fisher ScientificThermo Fisher Scientific markets NGS know-how underneath the Ion Torrent title. Final summer time, Thermo Fisher started partnering with the NIH’s Nationwide Most cancers Institute on the myeloMATCH (Molecular Evaluation for Remedy Selection) precision medication umbrella trial. Utilizing Thermo Fisher’s NGS know-how to check sufferers’ bone marrow and blood for genetic biomarkers, medical websites goal to match sufferers extra shortly with probably the most appropriate medical trial assessing a therapy focusing on particular mutations. Sequencing is inside Thermo Fisher’s Life Sciences Options section, which in 2024 generated $9.631 billion (22.5%) of the corporate’s $42.879 billion in income. |
Ultima GenomicsUltima Genomics, on February 24, commercially launched its UG 100 Solaris™ sequencing system, an improve of the UG 100™ sequencing platform launched final yr that options new chemistry, software program, and simplified workflows designed to considerably enhance output and decrease value. Solaris gives a >50% enhance in output to 10 to 12 billion reads per wafer, and a 20% value discount to 24 cents per million reads—a value Ultima says permits the $80 genome. Privately held Ultima emerged from stealth in 2022, elevating roughly $600 million. |
Suppliers of Sanger Sequencing Instrumentation |
Hitachi Excessive-TechHitachi Excessive-Tech joined Nabsys 2.0 on February 21 to disclose 15 awardees of their OhmX Speedy Software to Market Penetration Consumer Partnership (RAMP UP) Grant Program. Winners are pursuing quite a few functions of the OhmX Analyzer for structural variant evaluation, together with orthogonal affirmation of long-read sequencing calls. Hitachi markets the Compact CE Sequencer DS3000, designed to facilitate sequencing evaluation and fragment evaluation. For the fiscal yr ending March 31, 2024, Hitachi Excessive-Tech reported roughly ¥670.449 billion ($4.463 billion) in income. |
PromegaPrivately-held Promega markets the Spectrum Compact Capillary Electrophoresis (CE) system, a benchtop instrument supporting Sanger sequencing functions for verification of NGS base calls. Additionally it is designed to substantiate profitable genome edits in remodeled cultures and to display screen secondary clones for profitable enhancing occasions utilizing CRISPR-Cas9 strategies. Spectrum Compact CE additionally helps next-generation 8-color STR kits and can be used for DNA fragment evaluation for forensic labs. |
Thermo Fisher ScientificThermo Fisher Scientific markets genetic analyzers and workflow instruments for Sanger sequencing underneath the Utilized Biosystems model. Final September, Thermo Fisher launched the Utilized Biosystems InnoviGene™ Suite, an intuitive, browser-based software program platform for automating and optimizing CE information evaluation, enabling 21 CFR Half 11 compliance. Utilized Biosystems’ SeqStudio Sequence techniques, such because the SeqStudio Flex Sequence Genetic Analyzer, are designed to research nucleic acids utilizing CE with Sanger sequencing or fragment evaluation and allow functions starting from easy focused sequencing to identification of SARS variants of concern. |
Suppliers of Workflow Options |
Agilent Applied sciencesPresident and CEO Padraig McDonnell isn’t quantifying Agilent’s genomics enterprise, which his predecessor Mike McMullen pegged at $500 million in FY 2023. In FY 2024, McDonnell stated, genomics “posted low single-digit progress” forward of expectations. Simon Might, senior VP and President of Agilent’s Life Sciences and Diagnostics Markets Group, cited the Magnis NGS Prep System (“continues to see implausible traction”) and Avida DNA Reagent Equipment (“very inspired”). |
QIAGENGenomics England chosen the QIAGEN Medical Information Base (and Revvity’s chemagic™ 360 automated nucleic extraction instrument) in January to assist the Era Examine, which goals to sequence the genomes of 100,000 newborns to display screen for >200 chosen genetic situations. QIAGEN stated progress in common consumables used on third-party NGS techniques supported the 1% year-over-year enhance in This fall 2024 gross sales for its Genomics/NGS enterprise, to $66 million. Full-year genomics/NGS gross sales slid 2% to $234 million. |
RevvityRvvity agreed in January to mix its automated NGS workflow with Factor Bioscience’s AVITI system to co-develop a complete in vitro diagnostic (IVD) workflow resolution for neonatal sequencing. As a part of its new child sequencing analysis workflow, Revvity markets and commercializes to its NGS clients Bionano Genomics’ VIA™ software program. Revvity, previously Perkin Elmer’s diagnostics and life sciences enterprise, completed 2024 with a $12.686 million internet loss on income that inched up 0.1% to $2.755 billion. |
